Picture1.jpg
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
May 03, 2022 08:00 ET | Imago Biosciences, Inc.
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and...
Picture1.jpg
Imago BioSciences to Host Virtual Investor Event
December 01, 2021 08:00 ET | Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Picture1.jpg
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
November 11, 2021 16:05 ET | Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Picture1.jpg
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
November 10, 2021 16:05 ET | Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
CPI Logo-Color.png
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
June 11, 2021 09:00 ET | Constellation Pharmaceuticals , Inc.
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...
CPI Logo-Color.png
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
May 31, 2021 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET | Constellation Pharmaceuticals , Inc.
Dosing underway in the Phase 3 MANIFEST-2 clinical trialRecommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohortsUpcoming data presentation at ASCO...
CPI Logo-Color.png
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
January 07, 2021 09:30 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
CPI Logo-Color.png
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
December 06, 2020 08:00 ET | Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
Geron-logo-black-xsmall.png
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET | Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...